42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM)

Burges, Alexander; Wimberger, Pauline; Gorbounova, Vera; Sommer, H.; Schmalfeldt, Barbara; Pfisterer, J.; Ströhlein, Michael A.; Личиницер, М. Р.; Makhson, A N

doi:10.1016/s1359-6349(03)90076-0

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase III trial is planned to confirm these results. Other antibodies targeted against ovarian malignant cells have entered clinical development, such as the trifunctional removab -which has been administered intraperitoneally with encouraging results (87) .…”

Section: Novel Biological Agentsmentioning

confidence: 99%

Remaining controversies in the upfront management of advanced ovarian cancer

Mano

Awada

Minisini

et al. 2004

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. In the last decades, a lot of energy and resources have been put into a number of clinical trials, with some success. Nevertheless, the prognosis of patients diagnosed with advanced disease remains extremely poor. As research moved forward, some crucial questions with regard to the optimal upfront management of patients with advanced OC (AOC) have remained unanswered. In this article, we review the rationale behind these controversial issues, and provide the levels of evidence supporting the current recommendations for AOC management.

show abstract

Section: Novel Biological Agentsmentioning

confidence: 99%